ZYBERNO
Stock Report
Updated Aug 30, 2026

CENTESSA PHARMACEUTICALS PLC (CNTA)

Healthcare • NASDAQ

$40.50

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
CENTESSA PHARMACEUTICALS PLC (CNTA) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-60.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.24x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-29.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CENTESSA PHARMACEUTICALS PLC (CNTA) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CNTA generated -$142.09M in Owner Earnings. Capital was deployed as follows: $34.00K invested in capital expenditures. Reinvestment rate: 0.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:40.50
Market Cap:$6.22B

Valuation Multiples (2)

P/B Ratio:12.76x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$6.38B

Price Action & Momentum (1)

% of 52-Week High:99.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-44.2%
Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:-1,705.0%

Yield Metrics (2)

Earnings Yield:-$4.40
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-245.0%
Latest Earnings Filed:2026-05-05
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.53x
Quick Ratio:9.53x
Cash Ratio:1.71x

Leverage Analysis (3)

Debt To Equity Ttm:0.24x
Debt-to-Equity Ratio:0.24x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-18.36x
Times Interest Earned:-18.36

Capital Structure (4)

Working Capital:312,105,000.00
Cash And Cash Equivalents:62,431,000.00
Long Term Debt:$110.44M
Net Debt:$163.51M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$15.00M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$256.69M

Bottom Line Performance (3)

-$250.64M
Income Before Tax:-$249.37M
Ebitda Ttm:-255,745,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:198,672,000.00
Sga Expense:58,016,000.00
Income Tax Expense:$3.45M
Interest Expense:11,313,000.00

Expense Ratios (1)

Ebitda Margin:-1,705.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$641.76M
Current Assets:$348.68M
Ppe Net:722,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:154,415,000.00
Current Liabilities:36,574,000.00
Long Term Debt:$110.44M
Short Term Debt:$115.50M

Equity & Capital (3)

Equity:$487.35M
Retained Earnings:-$1.27B
Common Stock:222,480,776.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:10,658,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:10,565,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$208.80M-$208.83M

Investment Activities (2)

Investing Cash Flow:$42.71M
Capital Expenditures Ttm:34,000.00

Financing Activities (3)

Financing Cash Flow:$30.47M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:943,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.78
-$1.78
Earnings Per Share Ttm:-$1.63

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.26

Book Value & Capital (2)

Book Value Per Share:$3.17
Cash Per Share:0.41

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.05x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:259.34
Cash Conversion Cycle:-2,257.34
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$142.09M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-0.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:CNTA
Company Name:CENTESSA PHARMACEUTICALS PLC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United Kingdom

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:153.55M
Shares Outstanding Basic:153.55M
Shares Outstanding Diluted:153.55M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 01:03:57 UTC
Data Timestamp:2026-08-30T01:03:57.157290
Scroll to Top